Drugs & Aging

, Volume 25, Issue 3, pp 241–253

Cardiovascular Implications of Chronic Kidney Disease in Older Adults

  • Ramnath Dukkipati
  • Sharon Adler
  • Rajnish Mehrotra
Review Article


Because serum creatinine is an imprecise indicator of glomerular filtration rate (GFR), estimating equations derived from the Modification of Diet in Renal Diseases study are increasingly being used to estimate GFR. The notion that GFR declines with aging is based largely on the results of cross-sectional studies that have generally not differentiated the effects of senescence from those of coexisting conditions such as hypertension. Nevertheless, GFR probably declines in many, if not all, aging individuals. The introduction of automated reporting of estimated GFR may result in an over-diagnosis of chronic kidney disease (CKD). There is a large body of evidence to suggest that a decrease in GFR and/or albuminuria is associated with an increased risk of death, particularly from cardiovascular causes, and that this risk extends to the elderly. Although the data are not consistent with regard to the level of GFR at which the increase in cardiovascular risk becomes apparent, small amounts of urine albumin excretion (levels that do not meet the definition of microalbuminuria) are associated with a higher risk of death, even among the elderly. There is currently no evidence that aggressive control of blood pressure and/or use of medications that reduce proteinuria, such as those that block the renin-angiotensin-aldosterone system, reduce the risk of cardiovascular events or death among individuals with CKD. On the other hand, secondary analyses of at least two studies have documented the benefit of lipid lowering in CKD patients. Paradoxically, a recent study has raised concern that normalizing haemoglobin may enhance the cardiovascular risk associated with CKD. To conclude, the available evidence indicates that early identification of CKD may allow physicians to aggressively modify cardiovascular risk, which, in turn, has the potential to improve patient outcomes.


  1. 1.
    Levey AS. Use of glomerular filtration rate measurements to assess the progression of renal disease. Semin Nephrol 1989; 9: 370–9PubMedGoogle Scholar
  2. 2.
    Shemesh O, Golbetz H, Kriss JP, et al. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985; 28: 830–8PubMedCrossRefGoogle Scholar
  3. 3.
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41PubMedCrossRefGoogle Scholar
  4. 4.
    Goldberg TH, Finkelstein MS. Difficulties in estimating glomerular filtration rate in the elderly. Arch Intern Med 1987; 147: 1430–3PubMedCrossRefGoogle Scholar
  5. 5.
    Nicoll SR, Sainsbury R, Bailey RR, et al. Assessment of creatinine clearance in healthy subjects over 65 years of age. Nephron 1991; 59: 621–5PubMedCrossRefGoogle Scholar
  6. 6.
    National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002 Feb; 39 (2 Suppl. 1): S1–266CrossRefGoogle Scholar
  7. 7.
    Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461–70PubMedGoogle Scholar
  8. 8.
    Stevens LA, Coresh J, Greene T, et al. Assessing kidney function: measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473–83PubMedCrossRefGoogle Scholar
  9. 9.
    Epstein M. Aging and the kidney. J Am Soc Nephrol 1996; 7: 1106–22PubMedGoogle Scholar
  10. 10.
    Davies DF, Shock NW. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest 1950; 29: 496–507PubMedCrossRefGoogle Scholar
  11. 11.
    Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline of renal function with age. J Am Geriatr Soc 1985; 33: 278–85PubMedGoogle Scholar
  12. 12.
    Bleyer AJ, Shemanski LR, Burke GL, et al. Tobacco, hypertension, and vascular disease: risk factors for renal functional decline in an older population. Kidney Int 2000; 57: 2072–9PubMedCrossRefGoogle Scholar
  13. 13.
    Hemmelgarn BR, Zhang J, Manns BJ, et al. Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int 2006; 69: 2155–61PubMedCrossRefGoogle Scholar
  14. 14.
    Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41(1): 1–12PubMedCrossRefGoogle Scholar
  15. 15.
    Garg AX, Clark WF, Haynes RB, et al. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int 2002; 61: 1486–94PubMedCrossRefGoogle Scholar
  16. 16.
    Rule AD, Larson TS, Bergstralh EJ, et al. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 2004; 141: 929–3PubMedGoogle Scholar
  17. 17.
    Froissait M, Rossert J, Jacquot C, et al. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol 2005; 16: 763–73CrossRefGoogle Scholar
  18. 18.
    Poggio ED, Wang X, Greene T, et al. Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol 2005; 16: 459–66PubMedCrossRefGoogle Scholar
  19. 19.
    United States Renal Data System. Annual data report. Bethesda (MD): US Department of Public Health and Human Services, Public Health Service, National Institutes of Health, 2006Google Scholar
  20. 20.
    Hsu CY, Vittinghoff E, Lin F, et al. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med 2004; 141: 95–101PubMedGoogle Scholar
  21. 21.
    Muntner P, Coresh J, Powe NR, et al. The contribution of increased diabetes prevalence and improved myocardial infarction and stroke survival to the increase in treated end-stage renal disease. J Am Soc Nephrol 2003; 14: 1568–77PubMedCrossRefGoogle Scholar
  22. 22.
    Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42(5): 1050–65PubMedCrossRefGoogle Scholar
  23. 23.
    Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17: 2034–47PubMedCrossRefGoogle Scholar
  24. 24.
    Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659–63PubMedCrossRefGoogle Scholar
  25. 25.
    Rahman M, Pressel S, Davis BR, et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med 2006; 144: 172–80PubMedGoogle Scholar
  26. 26.
    Manjunath G, Tighiouart H, Coresh J, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003; 63: 1121–9PubMedCrossRefGoogle Scholar
  27. 27.
    Henry RM, Kostense PJ, Bos G, et al. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 2002; 62: 1402–7PubMedCrossRefGoogle Scholar
  28. 28.
    Mann JF, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629–36PubMedGoogle Scholar
  29. 29.
    Ruilope LM, Salvetti A, Jamerson K, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) study. J Am Soc Nephrol 2001; 12: 218–25PubMedGoogle Scholar
  30. 30.
    Shlipak MG, Simon JA, Grady D, et al. Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. J Am Coll Cardiol 2001; 38: 705–11PubMedCrossRefGoogle Scholar
  31. 31.
    McClellan WM, Flanders WD, Langsten RD, et al. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 2002; 13: 1928–36PubMedCrossRefGoogle Scholar
  32. 32.
    Smith GL, Shlipak MG, Havranek EP, et al. Race and renal impairment in heart failure: mortality in blacks versus whites. Circulation 2005; 111: 1270–7PubMedCrossRefGoogle Scholar
  33. 33.
    Dries DL, Exner DV, Domanski MJ, et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000; 35: 681–9PubMedCrossRefGoogle Scholar
  34. 34.
    De Leeuw PW, Thijs L, Birkenhager WH, et al. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial. J Am Soc Nephrol 2002; 13: 2213–22PubMedCrossRefGoogle Scholar
  35. 35.
    Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004 Sep 23; 351(13): 1285–95PubMedCrossRefGoogle Scholar
  36. 36.
    Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Intern Med 1997; 157(13): 1413–8PubMedCrossRefGoogle Scholar
  37. 37.
    Anavekar NS, Gans DJ, Berl T, et al. Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. Kidney Int Suppl 2004 Nov; 92: S50–5PubMedCrossRefGoogle Scholar
  38. 38.
    Damsgaard EM, Froland A, Jorgensen OD, et al. Microalbuminuria as predictor of increased mortality in elderly people. BMJ 1990; 3: 297–300CrossRefGoogle Scholar
  39. 39.
    Yuyun MF, Khaw KT, Luben R, et al. Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: the European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. Int J Epidemiol 2004; 33: 189–98PubMedCrossRefGoogle Scholar
  40. 40.
    Culleton BF, Larson MG, Parfrey PS, et al. Proteinuria as a risk factor for cardiovascular disease and mortality in older people: a prospective study. Am J Med 2000; 109: 1–8PubMedCrossRefGoogle Scholar
  41. 41.
    Arnlov J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005; 112: 969–75PubMedCrossRefGoogle Scholar
  42. 42.
    Jager A, Kostense PJ, Ruhe HG, et al. et al. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol 1999; 19: 617–24PubMedCrossRefGoogle Scholar
  43. 43.
    Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421–6PubMedCrossRefGoogle Scholar
  44. 44.
    Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139: 901–6PubMedGoogle Scholar
  45. 45.
    Roest M, Banga JD, Janssen WM, et al. Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. Circulation 2001; 103: 3057–61PubMedCrossRefGoogle Scholar
  46. 46.
    Olsen MH, Wachtell K, Ibsen H, et al. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. J Hypertens 2006; 24: 775–81PubMedCrossRefGoogle Scholar
  47. 47.
    Wang TJ, Evans JC, Meigs JB, et al. Low-grade albuminuria and the risks of hypertension and blood pressure progression. Circulation 2005; 111: 1370–6PubMedCrossRefGoogle Scholar
  48. 48.
    Ruggenenti P, Remuzzi G. Time to abandon microalbuminuria? Kidney Int 2006; 70: 1214–22PubMedCrossRefGoogle Scholar
  49. 49.
    Mehrotra R. Disordered mineral metabolism and vascular calcification in nondialyzed chronic kidney disease patients. J Ren Nutr 2006; 16: 100–18PubMedCrossRefGoogle Scholar
  50. 50.
    Mehrotra R, Budoff MJ, Christenson P, et al. Determinants of coronary artery calcification in diabetics with and without nephropathy. Kidney Int 2004; 66(5): 2022–31PubMedCrossRefGoogle Scholar
  51. 51.
    Stehouwer CD, Nauta JJ, Zeldenrust GC, et al. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992; 340(8815): 319–23PubMedCrossRefGoogle Scholar
  52. 52.
    Stehouwer CD, Smulders YM. Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. J Am Soc Nephrol 2006; 17: 2106–11PubMedCrossRefGoogle Scholar
  53. 53.
    Stehouwer CD, Henry RM, Dekker JM, et al. Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction. The HOORN study. Kidney Int Suppl 2004; 92: s42–4PubMedCrossRefGoogle Scholar
  54. 54.
    Rakhit DJ, Marwick TH, Armstrong KA, et al. Effect of aggressive risk factor modification on cardiac events and myocardial ischaemia in patients with chronic kidney disease. Heart 2006; 92: 1402–8PubMedCrossRefGoogle Scholar
  55. 55.
    Sarnak MJ, Greene T, Wang X, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 2005; 142: 342–51PubMedGoogle Scholar
  56. 56.
    Norris K, Bourgoigne J, Gassman J, et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) trial. Am J Kidney Dis 2006; 48: 739–51PubMedCrossRefGoogle Scholar
  57. 57.
    Asselbergs FW, Diercks GF, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004 Nov 2; 110(18): 2809–16PubMedCrossRefGoogle Scholar
  58. 58.
    Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–9PubMedCrossRefGoogle Scholar
  59. 59.
    Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345(12): 851–60PubMedCrossRefGoogle Scholar
  60. 60.
    Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–58PubMedCrossRefGoogle Scholar
  61. 61.
    Tonelli M, Moye L, Sacks FM, et al. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003; 138: 98–104PubMedGoogle Scholar
  62. 62.
    Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071–84PubMedCrossRefGoogle Scholar
  63. 63.
    Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085–98PubMedCrossRefGoogle Scholar
  64. 64.
    Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291: 565–75PubMedCrossRefGoogle Scholar
  65. 65.
    Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006 Apr 13; 354(15): 1578–88PubMedCrossRefGoogle Scholar
  66. 66.
    Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006 Apr 13; 354(15): 1567–77PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Ramnath Dukkipati
    • 1
    • 2
  • Sharon Adler
    • 1
    • 2
  • Rajnish Mehrotra
    • 1
    • 2
  1. 1.Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterTorranceUSA
  2. 2.David Geffen School of Medicine at UCLALos AngelesUSA
  3. 3.TorranceUSA

Personalised recommendations